Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANVS NYSEAMERICAN:APHB NASDAQ:ONC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$2.33-0.9%$2.56$1.11▼$10.54$45.40M1.65421,801 shs167,919 shsAPHBAmpliphi Biosciences$2.88-3.7%$2.59$0.15▼$1.37$96.39MN/A842,200 shs3,582 shsONCBeOne Medicines$334.40-2.5%$308.71$170.99▼$351.27$36.65B0.21424,304 shs241,895 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio+1.07%-1.05%-9.20%-9.65%-71.77%APHBAmpliphi Biosciences0.00%-3.35%+12.95%+50.79%+26.60%ONCBeOne Medicines+3.22%+2.15%+9.72%+38.78%+34,288,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$2.33-0.9%$2.56$1.11▼$10.54$45.40M1.65421,801 shs167,919 shsAPHBAmpliphi Biosciences$2.88-3.7%$2.59$0.15▼$1.37$96.39MN/A842,200 shs3,582 shsONCBeOne Medicines$334.40-2.5%$308.71$170.99▼$351.27$36.65B0.21424,304 shs241,895 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio+1.07%-1.05%-9.20%-9.65%-71.77%APHBAmpliphi Biosciences0.00%-3.35%+12.95%+50.79%+26.60%ONCBeOne Medicines+3.22%+2.15%+9.72%+38.78%+34,288,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANVSAnnovis Bio 2.60Moderate Buy$17.33643.92% UpsideAPHBAmpliphi Biosciences 0.00N/AN/AN/AONCBeOne Medicines 3.00Buy$336.300.57% UpsideCurrent Analyst Ratings BreakdownLatest ANVS, SCLP, APHB, REDX, and ONC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/18/2025ONCBeOne MedicinesBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$385.009/3/2025ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $10.008/8/2025ANVSAnnovis BioZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/7/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$349.00 ➝ $364.008/7/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$350.00 ➝ $365.007/17/2025ONCBeOne MedicinesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$321.00 ➝ $345.007/16/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$311.00 ➝ $349.006/27/2025ONCBeOne MedicinesMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$313.00 ➝ $330.006/27/2025ONCBeOne MedicinesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$317.00 ➝ $321.006/27/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$311.00(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANVSAnnovis BioN/AN/AN/AN/A$0.67 per shareN/AAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/AN/AONCBeOne Medicines$4.56B8.03N/AN/A$34.10 per share9.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANVSAnnovis Bio-$24.59M-$2.04N/AN/AN/AN/A-206.01%-158.26%11/14/2025 (Estimated)APHBAmpliphi BiosciencesN/AN/A0.00∞N/AN/AN/AN/AN/AONCBeOne Medicines-$644.79M-$1.73N/A470.99N/A-3.89%-1.22%-0.72%N/ALatest ANVS, SCLP, APHB, REDX, and ONC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ANVSAnnovis Bio-$0.36-$0.32+$0.04-$0.32N/AN/A8/6/2025Q2 2025ONCBeOne Medicines$0.48$0.84+$0.36$0.84$1.24 billion$1.32 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANVSAnnovis BioN/AN/AN/AN/AN/AAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/AONCBeOne MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANVSAnnovis BioN/A7.657.65APHBAmpliphi BiosciencesN/AN/AN/AONCBeOne Medicines0.041.951.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANVSAnnovis Bio15.83%APHBAmpliphi BiosciencesN/AONCBeOne Medicines48.55%Insider OwnershipCompanyInsider OwnershipANVSAnnovis Bio20.80%APHBAmpliphi BiosciencesN/AONCBeOne Medicines6.62%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANVSAnnovis Bio319.49 million15.43 millionOptionableAPHBAmpliphi Biosciences3033.47 millionN/ANot OptionableONCBeOne Medicines11,000109.60 million102.34 millionN/AANVS, SCLP, APHB, REDX, and ONC HeadlinesRecent News About These CompaniesBeOne Medicines (NASDAQ:ONC) CEO Sells $9,055,715.13 in Stock3 hours ago | marketbeat.comBeOne Medicines (NASDAQ:ONC) Now Covered by BarclaysSeptember 19 at 8:32 AM | marketbeat.comJohn Oyler Sells 27,803 Shares of BeOne Medicines (NASDAQ:ONC) StockSeptember 19 at 6:38 AM | insidertrades.comBarclays Initiates Coverage of BeOne Medicines AG - Depositary Receipt (ONC) with Overweight RecommendationSeptember 18 at 3:02 PM | msn.comBeOne Medicines initiated with an Overweight at BarclaysSeptember 18 at 9:35 AM | msn.comInsider Selling: BeOne Medicines (NASDAQ:ONC) SVP Sells 10,006 Shares of StockSeptember 14, 2025 | marketbeat.comCitizens JMP Maintains a Buy Rating on BeOne Medicines (ONC)September 14, 2025 | msn.comInsider Selling: BeOne Medicines (NASDAQ:ONC) Insider Sells 5,000 Shares of StockSeptember 13, 2025 | marketbeat.comBeOne Medicines (NASDAQ:ONC) Shares Gap Up - Still a Buy?September 13, 2025 | marketbeat.comChan Henry Lee Sells 10,006 Shares of BeOne Medicines (NASDAQ:ONC) StockSeptember 13, 2025 | insidertrades.comBeOne Medicines (NASDAQ:ONC) Shares Gap Down on Insider SellingSeptember 12, 2025 | marketbeat.comBeOne Medicines (NASDAQ:ONC) Director Sells $898,105.00 in StockSeptember 11, 2025 | marketbeat.comBeOne Medicines Honored with the Global Oncology Innovation Leadership Award at BIOHK 2025, Supporting "1+" to Accelerate the Delivery of Innovative Cancer TherapiesSeptember 11, 2025 | manilatimes.netMBeOne Medicines (NASDAQ:ONC) Shares Gap Down After Insider SellingSeptember 11, 2025 | americanbankingnews.comWhite House mulls restrictions on medicines invented in China: NYTSeptember 10, 2025 | msn.comChina-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive OrderSeptember 10, 2025 | msn.comPharma’s new boomtown? Why drugmakers are setting up shop in a small Swiss city.September 10, 2025 | finance.yahoo.comBeOne Medicines (NASDAQ:ONC) Reaches New 12-Month High - Still a Buy?September 10, 2025 | marketbeat.comBeOne Medicines (NASDAQ:ONC) Director Corazon (Corsee) Sanders Sells 2,665 SharesSeptember 10, 2025 | insidertrades.comBeOne Medicines AG (ONC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 8, 2025 | seekingalpha.comBeOne Medicines (NASDAQ:ONC) Cut to Buy at Wall Street ZenSeptember 8, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANVS, SCLP, APHB, REDX, and ONC Company DescriptionsAnnovis Bio NYSE:ANVS$2.33 -0.02 (-0.85%) Closing price 03:59 PM EasternExtended Trading$2.32 -0.01 (-0.43%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Ampliphi Biosciences NYSEAMERICAN:APHB$2.88 -0.11 (-3.68%) As of 09/16/2025AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections. It holds collaborative research and development agreements with the United States Army Medical Research and Materiel Command for the development of bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and Walter Reed Army Institute of Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.BeOne Medicines NASDAQ:ONC$334.40 -8.49 (-2.48%) As of 04:00 PM EasternBeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Azure Leads While AI Excitement Fuels Microsoft Stock The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Workday Rising… To Fresh Record High Stock Prices 3 Reasons Amazon Could Be at an All-Time High by October Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
